{
    "clinical_study": {
        "@rank": "148013", 
        "arm_group": [
            {
                "arm_group_label": "E10030 + bevacizumab or aflibercept", 
                "arm_group_type": "Experimental", 
                "description": "E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection"
            }, 
            {
                "arm_group_label": "Sham + bevacizumab or aflibercept", 
                "arm_group_type": "Active Comparator", 
                "description": "E10030 sham intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to evaluate the safety and efficacy  of  intravitreal\n      administration of Fovista\u2122  administered in combination with either Avastin\u00ae or Eylea\u00ae\n      compared to Avastin\u00ae   or Eylea\u00ae monotherapy in subjects with subfoveal choroidal\n      neovascularization secondary to age-related macular degeneration (AMD)."
        }, 
        "brief_title": "A Phase 3 Safety and Efficacy Study of Fovista\u2122 (E10030) Intravitreous Administration in Combination With Either Avastin\u00ae or Eylea\u00ae Compared to Avastin\u00ae or Eylea\u00ae Monotherapy", 
        "condition": "Age-Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "Subjects will be randomized in a 1:1 ratio to the following dose groups:\n\n        -  Fovista\u2122 1.5 mg/eye + Avastin\u00ae 1.25 mg/eye or Eylea\u00ae 2 mg/eye\n\n        -  Fovista\u2122 sham + Avastin\u00ae 1.25 mg/eye or Eylea\u00ae 2 mg/eye\n\n      Subjects will be treated for a total of 24 months with active Fovista\u2122 or sham in\n      combination with either Avastin\u00ae or Eylea\u00ae with the primary endpoint at 12 months.\n\n      Primary Efficacy Endpoint:\n\n      The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from\n      baseline at the month 12 visit.\n\n      Safety Endpoints:\n\n      Safety endpoints include adverse events, vital signs, ophthalmic variables [ophthalmic\n      examination, intraocular pressure (IOP), fluorescein angiogram (FA), optical coherence\n      tomography (OCT)], ECG, and laboratory variables.\n\n      Approximately 622 subjects will be randomized into one of the two treatment cohorts (311\n      patients per dose group)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects of either gender aged \u2265 50 years\n\n          -  Subfoveal choroidal neovascularization (CNV) due to AMD with some classic component\n\n        Exclusion Criteria:\n\n          -  Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral\n             supplements of vitamins and minerals.\n\n          -  Any prior intravitreal treatment in the study eye prior to the Day 1 visit,\n             regardless of indication (including intravitreal corticosteroids).\n\n          -  Any intraocular surgery or thermal laser within three (3) months of trial entry. Any\n             prior thermal laser in the macular region, regardless of indication.\n\n          -  Subjects with subfoveal scar or subfoveal atrophy are excluded\n\n          -  Diabetes mellitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "622", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940887", 
            "org_study_id": "OPH1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "E10030 + bevacizumab or aflibercept", 
                "intervention_name": "E10030", 
                "intervention_type": "Drug", 
                "other_name": "Fovista\u2122"
            }, 
            {
                "arm_group_label": [
                    "E10030 + bevacizumab or aflibercept", 
                    "Sham + bevacizumab or aflibercept"
                ], 
                "description": "Patients are randomized to receive either bevacizumab or aflibercept", 
                "intervention_name": "bevacizumab  or  aflibercept", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Avastin\u00ae", 
                    "Eylea\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Sham + bevacizumab or aflibercept", 
                "description": "Pressure on the eye with a syringe with no needle", 
                "intervention_name": "E10030 sham intravitreal injection", 
                "intervention_type": "Drug", 
                "other_name": "Sham"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Wet AMD", 
            "choroidal neovascularization", 
            "Fovista\u2122", 
            "E10030", 
            "Avastin\u00ae", 
            "Eylea\u00ae"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista\u2122 (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin\u00ae or Eylea\u00ae Compared to Avastin\u00ae or Eylea\u00ae Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.", 
        "overall_contact": {
            "email": "Karen.Lewis@ophthotech.com", 
            "last_name": "Karen Lewis", 
            "phone": "212-845-8223"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline at the month 12 visit.", 
            "measure": "Mean change in visual acuity from baseline at the Month 12 visit.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ophthotech Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ophthotech Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}